Advertisement

Lidocaine Injection

[14 January 2016]

Products Affected - Description

Xylocaine injection, Fresenius Kabi
1%, 20 mL vial, 25 count, (NDC 63323-0485-27)
 
Xylocaine-MPF injection, Fresenius Kabi
2%, 10 mL ampule, 5 count (NDC 63323-0496-97)
 
Lidocaine Hydrochloride injection, Amphastar
2%, 5 mL Luer-Jet emergency syringes, 10 count (NDC 76329-3390-01)
 
Lidocaine Hydrochloride injection, AuroMedics
1%, 5 mL vial, 10 count (NDC 55150-0162-05)
1%, 30 mL vial, 1 count, NDC 55150-0163-30)
2%, 2 mL vial, 10 count, NDC 55150-0164-02)
2%, 5 mL vial, 10 count, NDC 55150-0165-05)
 
Lidocaine Hydrochloride injection, Fresenius Kabi
1%, 2 mL vial, 25 count (NDC 63323-0201-02)
1%, 10 mL vial, 25 count (NDC 63323-0201-10)
2%, 2 mL vial, 25 count (NDC 63323-0202-02)
2%, 5 mL SD Tear Top vial, preservative-free, 25 count (NDC 63323-0208-05)
 
Lidocaine Hydrochloride injection, Hospira
1%, 5 mL LifeShield syringe, 10 count (NDC 00409-4904-34)
1.5%, 20 mL sterile pack, glass ampule, preservative-free, 5 count (NDC 00409-4056-01)
2%, 5 mL LifeShield syringe, 10 count (NDC 00409-4903-34)
2%, 5 mL preservative-free vial, 10 count (NDC 00409-2066-05)

Reason for the Shortage

  • Amphastar had lidocaine 2% emergency syringes on shortage due to increase demand for the product.
  • AuroMedics introduced lidocaine injection in February 2014.
  • Fresenius Kabi has generic lidocaine presentations on shortage due to a supply interruption of API. Xylocaine products are not affected.
  • Hospira has lidocaine presentations on shortage due to manufacturing delays and increased demand.

Available Products

Xylocaine injection, Fresenius Kabi
0.5%, 50 mL vial, 25 count (NDC 63323-0484-57)
1%, 50 mL vial, 25 count (NDC 63323-0485-57)
2%, 10 mL vial, 25 count (NDC 63323-0486-17)
2%, 20 mL vial, 25 count (NDC 63323-0486-27)
2%, 50 mL vial, 25 count (NDC 63323-0486-57)
 
Xylocaine-MPF injection, Fresenius Kabi
0.5%, 50 mL vial, 25 count (NDC 63323-0491-57)
1%, 2 mL vial, 25 count (NDC 63323-0492-27)
1%, 5 mL vial, 25 count (NDC 63323-0492-57)
1%, 30 mL sterile-pack vial, 5 count (NDC 63323-0492-31)
1%, 30 mL vial, 25 count (NDC 63323-0492-37)
1.5%, 10 mL ampule, 5 count (NDC 63323-0493-97)
1.5%, 20 mL ampule, 5 count (NDC 63323-0493-91)
2%, 2 mL vial, 25 count (NDC 63323-0495-27)
2%, 5 mL vial, 25 count (NDC 63323-0495-07)
 
Lidocaine Hydrochloride injection, AuroMedics
1%, 2 mL ampule, 10 count (NDC 55150-0158-72)
1%, 2 mL vial, 10 count (NDC 55150-0161-02)
1%, 5 mL ampule, 10 count (NDC 55150-0159-74)
2%, 2 mL ampule, 10 count (NDC 55150-0160-72)
 
Lidocaine Hydrochloride injection, Hospira
0.5%, 50 mL SD Tear Top preservative-free vial, 25 count (NDC 00409-4278-01)
0.5%, 50 mL SD Flip Top vial, 25 count (NDC 00409-4275-01)
1%, 2 mL preservative-free glass ampule, 50 count (NDC 00409-4713-32)
1%, 5 mL emergency Ansyr syringe, 10 count (NDC 00409-9137-05)
1%, 5 mL preservative-free glass ampule, 50 count (NDC 00409-4713-02)
1%, 20 mL vial, 25 count (NDC 00409-4276-01)
1%, 30 mL sterile-pack preservative-free vial, 25 count (NDC 00409-4270-01)
1%, 30 mL preservative-free vial, 25 count (NDC 00409-4279-02)
1%, 50 mL vial, 25 count (NDC 00409-4276-02)
1.5%, 20 mL preservative-free ampule, 25 count (NDC 00409-4776-01)
2%, 2 mL preservative-free glass ampule, 25 count (NDC 00409-4282-01)
2%, 5 mL emergency Ansyr syringe, 10 count (NDC 00409-1323-05)
2%, 10 mL preservative-free glass ampule, 25 count (NDC 00409-4282-02)
2%, 20 mL vial, 25 count (NDC 00409-4277-01)
2%, 50 mL vial, 25 count (NDC 00409-4277-02)
4%, 5 mL preservative-free glass ampule, 25 count (NDC 00409-4283-01)

Estimated Resupply Dates

  • Amphastar has 2% lidocaine 5 mL syringes on intermittent back order and the company is regularly releasing product.
  • AuroMedics has 1% lidocaine 5 mL and 30 mL vials on intermittent back order and the company is releasing product as it becomes available. AuroMedics has 2% lidocaine 2 mL and 5 mL vials on intermittent back order and the company is releasing product as it becomes available.
  • Fresenius Kabi has 1% lidocaine 2 mL and 10 mL vials and 2% lidocaine 2 mL vials are on long-term back order and the company cannot estimate a release date. The 1% Xylocaine 20 mL vials are on intermittent back order and the company is releasing supplies as they become available. The 2% lidocaine 5 mL vials are on back order with an estimated release date of late-January 2016. The 2% Xylocaine-MPF 10 mL ampules are on back order with an estimated release date of early-February 2016.
  • Hospira has lidocaine 1.5% 20 mL ampules, preservative-free, in sterile pack on back order and the company cannot estimate a release date. The 2% lidocaine 5 mL vials are on allocation. The 1% lidocaine 5 mL LifeShield syringes are available in limited supply. The 2% lidocaine 5 mL LifeShield syringes are on back order with an estimated release date of May 2016.

Related Shortages

Updated

January 14, 13 and 6, 2016; December 17 and 3, November 12, October 19 and 12, September 25 and 10, August 25, June 23, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement